Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

This study has been completed.
Information provided by (Responsible Party):
Takeda Identifier:
First received: April 10, 2007
Last updated: May 4, 2012
Last verified: January 2012
The purpose of this study is to compare the systemic des-ciclesonide exposure of OMNARIS™ (ciclesonide) nasal spray, ciclesonide HFA nasal aerosol, and orally inhaled ciclesonide HFA-metered-dose inhaler (MDI). The administration of the study medication will be as follows: three single doses, separated by a wash-out period. The study will provide further data on the safety and tolerability of ciclesonide.

Condition Intervention Phase
Allergic Rhinitis
Drug: Ciclesonide
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Single-dose, 3-period Crossover, Pharmacokinetic Study Designed to Compare the Systemic Des-ciclesonide Exposure of OMNARIS™ (Ciclesonide) Nasal Spray, Ciclesonide HFA Nasal Aerosol, and Orally Inhaled Ciclesonide

Resource links provided by NLM:

Further study details as provided by Takeda:

Primary Outcome Measures:
  • To compare the systemic exposure to des-ciclesonide with OMNARIS™ (ciclesonide nasal spray), and ciclesonide HFA nasal aerosol and orally inhaled ciclesonide.

Secondary Outcome Measures:
  • Pharmacokinetic parameters, safety and tolerability of ciclesonide will also be assessed.

Estimated Enrollment: 30
Study Start Date: April 2007
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • Written informed consent and HIPAA
  • Body weight as indicate by a Body Mass Index (BMI) between ≥ 18 and ≤ 28 kg/m², and a body weight >50 kg
  • General good health
  • Ability to use oral inhaler

Main Exclusion Criteria:

  • Pregnancy, breast feeding, intention to become pregnant during the course of the study or lack of safe contraception in pre-menopausal women
  • Participation in any investigational drug trial within the 30 days before Screening Visit and thereafter
  • History or current clinically relevant allergies or idiosyncrasy to drugs or food
  • History of allergic reactions to any corticosteroids including ciclesonide or any excipients of the formulations
  • Any contraindication to nasally administered corticosteroids
  • History of a respiratory infection or disorder [including, but not limited to bronchitis, pneumonia, acute or chronic sinusitis, flu, severe acute respiratory syndrome (SARS)] within the 30 days before Screening Visit, or development of a respiratory infection during the Screening Period
  • History or current evidence of any other relevant allergic, cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrine, metabolic, neurological, psychiatric, or other disease within the last 2 years
  • Non-vaccinated exposure to or active infection with, chickenpox or measles within the 21 days preceding Screening Visit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00458835

United States, Texas
Austin, Texas, United States
Sponsors and Collaborators
Principal Investigator: Aziz L Laurent, MD PPD Development, LP, Austin , TX 78744
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Takeda Identifier: NCT00458835     History of Changes
Other Study ID Numbers: BY9010/M1-422 
Study First Received: April 10, 2007
Last Updated: May 4, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
Allergic rhinitis

Additional relevant MeSH terms:
Anti-Allergic Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on April 27, 2016